Usynova is devoted to addressing unsatisfied clinical needs, and providing accessible treatment regimens for patients worldwide through tackling refractory targets and key oncogenes. Holding an open and win-win attitude, the company welcomes CRO companies and pharmaceutical enterprises for project cooperation, aiming to accelerate clinical progress, promote the development of innovative drugs, and contribute to the welfare of patients.

We welcome discussions on strategic and creative cooperation, including but not limited to:

Our therapeutic areas of expertise and interest include: